Literature DB >> 12874399

Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology.

M A Pappolla1, T K Bryant-Thomas, D Herbert, J Pacheco, M Fabra Garcia, M Manjon, X Girones, T L Henry, E Matsubara, D Zambon, B Wolozin, M Sano, F F Cruz-Sanchez, L J Thal, S S Petanceska, L M Refolo.   

Abstract

BACKGROUND: Epidemiologic and experimental data suggest that cholesterol may play a role in the pathogenesis of AD. Modulation of cholesterolemia in transgenic animal models of AD strongly alters amyloid pathology.
OBJECTIVE: To determine whether a relationship exists between amyloid deposition and total cholesterolemia (TC) in the human brain.
METHODS: The authors reviewed autopsy cases of patients older than 40 years and correlated cholesterolemia and presence or absence of amyloid deposition (amyloid positive vs amyloid negative subjects) and cholesterolemia and amyloid load. Amyloid load in human brains was measured by immunohistochemistry and image analysis. To remove the effect of apoE isoforms on cholesterol levels, cases were genotyped and duplicate analyses were performed on apoE3/3 subjects.
RESULTS: Cholesterolemia correlates with presence of amyloid deposition in the youngest subjects (40 to 55 years) with early amyloid deposition (diffuse type of senile plaques) (p = 0.000 for all apoE isoforms; p = 0.009 for apoE3/3 subjects). In this group, increases in cholesterolemia from 181 to 200 almost tripled the odds for developing amyloid, independent of apoE isoform. A logistic regression model showed consistent results (McFadden rho2 = 0.445). The difference in mean TC between subjects with and without amyloid disappeared as the age of the sample increased (>55 years: p = 0.491), possibly reflecting the effect of cardiovascular deaths among other possibilities. TC and amyloid load were not linearly correlated, indicating that there are additional factors involved in amyloid accumulation.
CONCLUSIONS: Serum hypercholesterolemia may be an early risk factor for the development of AD amyloid pathology.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12874399     DOI: 10.1212/01.wnl.0000070182.02537.84

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  104 in total

Review 1.  Mild cognitive impairment and dementia: the importance of modifiable risk factors.

Authors:  Thorleif Etgen; Dirk Sander; Horst Bickel; Hans Förstl
Journal:  Dtsch Arztebl Int       Date:  2011-11-04       Impact factor: 5.594

2.  Cerebrovascular lesions induce transient β-amyloid deposition.

Authors:  Monica Garcia-Alloza; Julia Gregory; Kishore V Kuchibhotla; Sara Fine; Ying Wei; Cenk Ayata; Matthew P Frosch; Steven M Greenberg; Brian J Bacskai
Journal:  Brain       Date:  2011-11-26       Impact factor: 13.501

Review 3.  Neuronutrition and Alzheimer's disease.

Authors:  Balenahalli N Ramesh; T S Sathyanarayana Rao; Annamalai Prakasam; Kumar Sambamurti; K S Jagannatha Rao
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

4.  Rosuvastatin and thapsigargin modulate γ-secretase gene expression and APP processing in a human neuroglioma model.

Authors:  Alessio Crestini; Paola Piscopo; Mariavittoria Iazeolla; Diego Albani; Roberto Rivabene; Gianluigi Forloni; Annamaria Confaloni
Journal:  J Mol Neurosci       Date:  2010-10-28       Impact factor: 3.444

Review 5.  Cholesterol, 24-Hydroxycholesterol, and 27-Hydroxycholesterol as Surrogate Biomarkers in Cerebrospinal Fluid in Mild Cognitive Impairment and Alzheimer's Disease: A Meta-Analysis.

Authors:  Hua-Long Wang; Yan-Yong Wang; Xin-Gang Liu; Sheng-Han Kuo; Na Liu; Qiao-Yun Song; Ming-Wei Wang
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

Review 6.  Interventions for heart disease and their effects on Alzheimer's disease.

Authors:  Benjamin Wolozin; Martin M Bednar
Journal:  Neurol Res       Date:  2006-09       Impact factor: 2.448

Review 7.  Cholesterol as a causative factor in Alzheimer's disease: a debatable hypothesis.

Authors:  W Gibson Wood; Ling Li; Walter E Müller; Gunter P Eckert
Journal:  J Neurochem       Date:  2014-01-02       Impact factor: 5.372

8.  Donepezil effects on cholesterol and oxysterol plasma levels of Alzheimer's disease patients.

Authors:  Alana C Costa; Helena P G Joaquim; Valéria S Nunes; Daniel S Kerr; Guilherme S Ferreira; Orestes V Forlenza; Wagner F Gattaz; Leda Leme Talib
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-08-31       Impact factor: 5.270

Review 9.  Alzheimer's disease--a dysfunction in cholesterol and lipid metabolism.

Authors:  Walter J Lukiw; Miguel Pappolla; Ricardo Palacios Pelaez; Nicolas G Bazan
Journal:  Cell Mol Neurobiol       Date:  2005-06       Impact factor: 5.046

10.  Sex differences in the associations between lipid levels and incident dementia.

Authors:  Marie-Laure Ancelin; Emmanuelle Ripoche; Anne-Marie Dupuy; Pascale Barberger-Gateau; Sophie Auriacombe; Olivier Rouaud; Claudine Berr; Isabelle Carrière; Karen Ritchie
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.